Overview

Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of olanzapine and fluoxetine combined on all the visits as compared with the baseline visit in patients with bipolar disorder, measured by the total score of the Montgomery-Asberg Depression Rating Scale (MADRS).
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Fluoxetine
Olanzapine